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Abstract
Introduction Immunosuppressants, including anti-TNFα
antibodies, have remarkable effects in rheumatoid arthritis;
however, they increase infectious events. The present study was
designed to examine the effects and immunological change of
action of altered peptide ligands (APLs) on glucose-6-
phosphate isomerase (GPI) peptide-induced arthritis.
Methods DBA/1 mice were immunized with hGPI325-339, and
cells of draining lymph node (DLN) were stimulated with
hGPI325-339 to investigate the T-cell receptor (TCR) repertoire of
antigen-specific CD4+ T cells by flow cytometry. Twenty types of
APLs with one amino acid substitution at a TCR contact site of
hGPI325-339 were synthesized. CD4+ T cells primed with human
GPI and antigen-presenting cells were co-cultured with each
APL and cytokine production was measured by ELISA to identify
antagonistic APLs. Antagonistic APLs were co-immunized with
hGPI325-339 to investigate whether arthritis could be antigen-
specifically inhibited by APL. After co-immunization, DLN cells
were stimulated with hGPI325-339 or APL to investigate Th17 and
regulatory T-cell population by flow cytometry, and anti-mouse
GPI antibodies were measured by ELISA.
Results Human GPI325-339-specific Th17 cells showed
predominant usage of TCRVβ8.1 8.2. Among the 20
synthesized APLs, four (APL 6; N329S, APL 7; N329T, APL 12;
G332A, APL 13; G332V) significantly reduced IL-17
production by CD4+ T cells in the presence of hGPI325-339. Co-
immunization with each antagonistic APL markedly prevented
the development of arthritis, especially APL 13 (G332V).
Although co-immunization with APL did not affect the population
of Th17 and regulatory T cells, the titers of anti-mouse GPI
antibodies in mice co-immunized with APL were significantly
lower than in those without APL.
Conclusions We prepared antagonistic APLs that antigen-
specifically inhibited the development of experimental arthritis.
Understanding the inhibitory mechanisms of APLs may pave the
way for the development of novel therapies for arthritis induced
by autoimmune responses to ubiquitous antigens.
Introduction
Rheumatoid arthritis (RA) is characterized by symmetrical pol-
yarthritis and joint destruction. Although the etiology is consid-
ered autoimmune reactivity to some antigens, the exact
mechanisms are not fully understood. Pathological examina-
tions show that most of the lymphocytes infiltrating the syn-
ovium in RA are CD4+ T cells, which can recognize some
antigens and expand oligoclonally intraarticularly [1]. These
findings imply the possible role of CD4+ T cells in the patho-
genesis of RA. Previous studies showed that cytotoxic T-lym-
phocyte antigen-4 immunoglobulin and tacrolimus have
remarkable effects on RA, and stressed the importance of
CD4+ T cells in the pathogenesis of RA [2-4].
Ab: antibody; APC: antigen-presenting cell; APL: altered peptide ligand; CII: collagen type II; DLN: draining lymph node; ELISA: enzyme-linked immu-
nosorbent assay; GPI: glucose-6-phosphate isomerase; IFN: interferon; IL: interleukin; MBP: myelin basic protein; MHC: major histocompatibility com-
plex; PBS: phosphate-buffered saline; PLP: proteolipid protein; RA: rheumatoid arthritis; rhGPI: recombinant human glucose-6-phosphate isomerase; 
TCR: T-cell receptor; Th: T-helper; TNF: tumor necrosis factor.Arthritis Research & Therapy    Vol 11 No 6    Iwanami et al.
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Although the exact helper T-cell lineage critical in RA remains
elusive, previous animal studies reported that Th17 cells play
a crucial role and that Th1 cells may have a protective role
against the progress of arthritis in most mouse models with the
exception of proteoglycan-induced arthritis in Balb/c mice [5].
Collagen-induced arthritis in the C57BL/6 background is
markedly suppressed in IL-17-deficient mice [6], and glucose-
6-phosphate isomerase (GPI)-induced arthritis in the DBA/1
background and antigen-induced arthritis in the C57BL/6
background are also suppressed by the administration of anti-
IL-17 antibodies (Abs) [7,8]. In these models, complete Fre-
und's adjuvant is used for the induction of arthritis; therefore it
is possible that the components of Mycobacterium tuberculo-
sis affect the cytokine dependency. The arthritis seen in IL-1
receptor antagonist-deficient mice in the Balb/c background
and SKG mice in the Balb/c background, however, is com-
pletely suppressed in IL-17-deficient mice [9,10]. These find-
ings indicate that Th17 cells play a central role in murine
models independent of mouse strains and target antigens.
IL-17 is also considered to play a crucial role in host defense.
IL-17 signaling seems essential for the recruitment of neu-
trophils to the alveolar space in pneumonia caused by Kleb-
siella pneumoniae,  Mycoplasma pneumoniae and
Pneumocystis jiroveci [11-13]. IL-17 is also involved in
mucosal host defense against oropharyngeal candidasis via
salivary antimicrobial factors, in addition to neutrophil recruit-
ment [14]. Furthermore, IL-17 production by γδ T cells is
essential against peritonitis caused by Escherichia coli [15]. In
this regard, anti-cytokine therapies such as infliximab and
tocilizumab have been applied to clinical treatment and have
shown striking effects on RA [16-19]; anti-IL-17 therapy could
therefore be useful in the treatment of RA. Blockade of IL-17
could increase the likelihood of infections, however, and the
use of such a strategy would be limited just like the case of inf-
liximab and tocilizumab.
Altered peptide ligands (APLs) are peptides with substitutions
in amino acid residues at T-cell receptor (TCR) contact sites,
and can be either agonistic, antagonistic with partial activation
or antagonistic [20]. These three different actions seem to
depend on the site and residue of the peptide substitution
[21]. The antagonistic APLs can inhibit the function of limited
T-cell populations, and thus they could be potentially useful as
antigen-specific therapy for autoimmune diseases in which T
cells play a pathogenic role. Indeed, APLs have been proven
effective in the suppression of several autoimmune models. In
an arthritis model, previous studies identified type II collagen
CII245-270 as a prominent T-cell epitope in collagen-induced
arthritis in DBA/1 mice, and found that co-immunization with
the analog peptide (I260A, A261B(hydroxyproline), F263N),
also known as A9, significantly suppressed the disease
[22,23]. As reported previously, however, the type II collagen
residues CII 260 (I) and CII 263 (F) are I-Aq (MHC class II of
DBA/1 mice) binding sites, and A9 was confirmed not to bind
I-Aq molecules [24,25]. The analog peptide A9 therefore
seems to differ from conventional APLs, and the inhibitory
effect and the mechanisms of conventional APLs on arthritis
remain to be defined.
Several models of arthritis have so far been described and
analyzed to understand the etiological mechanisms of RA.
GPI-induced arthritis, a murine model of RA, is induced by
immunization of DBA/1 mice with recombinant human GPI
(rhGPI) [26]. We demonstrated previously that the Th17 sub-
set of CD4+ T cells played a central role in the pathogenesis
of GPI-induced arthritis; GPI-specific CD4+  T cells were
skewed to TH-17 at the time of onset, and blockade of IL-17
resulted in a significant amelioration of arthritis [7]. We have
also demonstrated that the major epitope of CD4+ T cells in
GPI-induced arthritis was hGPI325-339, and immunization with
the peptide induced severe polyarthritis (GPI peptide-induced
arthritis) [27].
The present work is an extension to the above studies. Specif-
ically, we explored the antigen-specific Th17 inhibition,
explored the effects of APLs on arthritis, and investigated the
inhibitory mechanisms of APLs, using the T-cell-dependent
model of GPI peptide-induced arthritis. The results showed
that many hGPI325-339-specific CD4+ T cells employed Vβ8.1
8.2 as the TCR repertoire, and co-immunization with APL
(N329S, N329T, G332A, or G332V) significantly inhibited the
development of arthritis. Our analysis of the inhibitory mecha-
nisms of APLs indicates that our APLs can function as TCR
antagonists; however, they can differentiate naïve CD4+ T
cells to Th17 cells, but not Th2 cells or regulatory T cells.
Based on these findings, we define a new aspect for APLs,
and propose that they may provide the basis for the invention
of new antigen-specific therapy.
Materials and methods
Mice
DBA/1 mice were purchased from Charles River Laboratories,
Yokohama, Japan. All mice were kept under specific patho-
gen-free conditions, and all experiments were conducted in
accordance with the institutional ethical guidelines.
Glucose-6-phosphate isomerase and synthetic peptides
The rhGPI and recombinant mouse GPI were prepared as
described previously [28,29]. Briefly, human or mouse GPI
cDNA was inserted into the plasmid pGEX-4T3 (Pharmacia,
Uppsala, Sweden) for expression of glutathione-S-transferase-
tagged proteins. E. coli harboring pGEX-hGPI plasmid was
allowed to proliferate at 37°C, before the addition of 0.1 mM
isopropyl-β-d-thiogalactopyranoside to the medium, followed
by further culture overnight at 30°C. The bacteria were lysed
with a sonicator and the supernatant was purified with a glu-
tathione-sepharose column (Pharmacia). The purity was esti-
mated by SDS-PAGE.Available online http://arthritis-research.com/content/11/6/R167
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Peptides for screening were synthesized with 70% purity by
Wako Pure Chemical Industries, Ltd (Osaka, Japan), and pep-
tides of a major peptide and antagonistic altered peptide lig-
ands were synthesized with 90% purity by Invitrogen
(Carlsbad, CA, USA). OVA323-339 peptide was purchased from
AnaSpec (San Jose, CA, USA).
Induction of arthritis
DBA/1 mice were immunized with 10 μg synthetic peptides
for GPI peptide-induced arthritis in complete Freund's adju-
vant (Difco Laboratories, Detroit, MI, USA), and in the indi-
cated experiments 50 μg altered peptide ligands were used
with 10 μg GPI325-339 for co-immunization. The synthetic pep-
tides were emulsified with complete Freund's adjuvant at a 1:1
ratio (v/v). For induction of arthritis, 150 μl emulsion was
injected intradermally at the base of the tail, and 200 ng per-
tussis toxin was injected intraperitoneally on days 0 and 2 after
immunization.
The arthritis score was evaluated visually using a score of 0 to
3 for each paw. A score of 0 represented no evidence of
inflammation, 1 represented subtle inflammation or localized
edema, 2 represented easily identified swelling that was local-
ized to either the dorsal or ventral surface of the paws, and 3
represented swelling in all areas of the paws.
Screening of antagonistic altered peptide ligands
Mice were sacrificed on the indicated day. Spleens and drain-
ing lymph nodes (DLNs) were harvested, and splenocytes
were hemolyzed with a solution of 0.83% NH4Cl, 0.12%
NaHCO3 and 0.004% EDTA2Na in PBS. Single-cell suspen-
sions were prepared in RPMI 1640 medium (Sigma-Aldrich,
St Louis, MO, USA) containing 10% fetal bovine serum, 100
U/ml penicillin, 100 μg/ml streptomycin and 50 μM 2-mercap-
toethanol. CD4+ T cells from DLNs and CD11c+ dendritic
cells from spleens were isolated by magenetic-activated cell
sorting (Miltenyi Biotec, Bergisch Gladbach, Germany). The
purity of the collected cells (>97%) was confirmed by flow
cytometry. CD11c+ dendritic cells treated with 50 μg/ml mito-
mycin C were used as antigen-presenting cells (APCs). The
purified CD4+ T cells and APCs were co-cultured with 10 μM
synthetic peptide at a ratio of 1:3 in 96-well round-bottom
plates (Nunc, Roskilde, Denmark) at 37°C under 5% carbon
dioxide for 72 hours. The supernatants were assayed for IL-10
and IL-17 by the Quantikine ELISA kit (R&D Systems, Minne-
apolis, MN, USA).
Pre-pulse assay
The pre-pulse assay was conducted as described previously
[30]. Briefly, CD11c+ APCs from spleens (4 × 104/well) were
cultured with a suboptimal concentration of GPI325-339 (3 μM)
for 2 hours. In the meantime, native peptides were loaded onto
APCs and presented on MHC. After 2 hours of incubation,
APCs were washed twice to remove unbound peptides, and
30 μM each antagonistic APL was added. After 18 hours of
culture, CD4+ T cells (2 × 104/well) from DLNs were added,
and after an additional 72 hours of culture the supernatants
were assayed for IL-17 and IL-10 by ELISA. The inhibition ratio
was calculated as follows:
1 − (IL-17 concentration in the presence of native peptides
and APLs / IL-17 concentration in the presence of native pep-
tides only) x 100 (%)
Flow cytometry
Mice were sacrificed on the indicated day. The popliteal lymph
nodes were harvested and single-cell suspensions were pre-
pared as described above. Cells (1 × 106/ml) were stimulated
with 100 μg/ml rhGPI in 96-well round-bottom plates (Nunc)
for 24 hours and GoldiStop (BD PharMingen, San Diego, CA,
USA) was added for the last 2 hours of each culture. Cells
were first stained extracellularly, fixed and permeabilized with
Cytofix/Cytoperm solution (BD PharMingen) and then stained
intracellularly. Regulatory T cells were stained with the Mouse
Regulatory T cell Staining kit (eBioscience, San Diego, CA,
USA) according to the protocol supplied by the manufacturer.
For TCR repertoire screening, the Mouse TCR Screening
Panel (BD PharMingen) was used. Samples were acquired on
FACSCalibur (BD PharMingen) and data were analyzed with
FlowJo (Tree Star, Ashland, OR, USA).
Analysis of anti-glucose-6-phosphate isomerase 
antibody
Sera were taken from immunized mice on day 28 and were
diluted 1:500 (for IgG, IgG2a, IgG2b and IgG3) or 1:8,000 (for
IgG1) in blocking solution (25% Block Ace (Dainippon Sumi-
tomo Pharma, Osaka, Japan) in PBS) for antibody analysis.
We also prepared 96-well plates (Sumitomo Bakelite, Tokyo,
Japan) coated with 5 μg/ml recombinant mouse GPI for 12
hours at 4°C. After washing twice with a washing buffer
(0.05% Tween20 in PBS), the blocking solution was used for
blocking nonspecific binding for 2 hours at room temperature.
After two washes, 150 μl diluted serum was added and incu-
bated for 2 hours at room temperature. After three washes,
alkaline phosphatase-conjugated anti-mouse IgG, horseradish
peroxidase-conjugated anti-mouse IgG1, IgG2a, IgG2b (Zymed
Laboratories, San Francisco, CA, USA) or IgG3 (Invitrogen)
was added at a final dilution of 1:5,000 for 1 hour at room tem-
perature. After three washes, color was developed with sub-
strate solution (1 alkaline phosphatase tablet (Sigma-Aldrich)
per 5 ml alkaline phosphatase reaction solution (containing
9.6% diethanolamine and 0.25 mM MgCl2, pH 9.8)) or tetram-
ethylbenzidine (KPL, Gaithersburg, MD, USA). Plates were
incubated for 20 to 60 minutes at room temperature and the
optical density was measured by a microplate reader at 405
nm (for IgG) or at 450 nm (for IgG1, IgG2a, IgG2b and IgG3).
Statistical analysis
All data are expressed as the mean ± standard error of the
mean or standard deviation. Differences between groups wereArthritis Research & Therapy    Vol 11 No 6    Iwanami et al.
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examined for statistical significance using the Mann-Whitney
U test. Differences of arthritis incidence between groups were
examined using Fisher's exact test. P < 0.05 denotes the pres-
ence of a statistically significant difference.
Results
Designing and screening antagonistic altered peptide 
ligands
We reported previously that the major T-cell epitope in GPI-
induced arthritis is hGPI325-339, and immunization with the
peptide provokes symmetrical polyarthritis (GPI peptide-
induced arthritis) [28]. To investigate the effects of APLs in
GPI peptide-induced arthritis, we first designed APLs of
hGPI325-339. Since the MHC binding sites of hGPI325-339 exist
at P1 (I328), P4 (F331), and P7 (E334) (IWYINCF-
GCETHAML) [25,28], the amino acid residues of the TCR
contact sites at P0 (Y327), P2 (N329), P3 (C330), P5
(G332), P6 (C333), and P8 (T335) were substituted for
another peptide to design 20 types of APLs (Table 1).
To select antagonistic APLs, CD4+ T cells primed with rhGPI
and APCs were co-cultured with each APL. The IL-17 produc-
tion was markedly lower with APL 2, APL 5, APL 6, APL 7, APL
9, APL 10, APL 11, APL 12, APL 13, and APL 18 than with
hGPI325-339, and therefore these APLs were considered can-
didates of antagonistic APLs (Figure 1a). None of the APLs
induced IL-4 and IL-10 production (data not shown). We next
explored the potency of the APLs in inhibiting IL-17 production
in the presence of hGPI325-339. In the pre-pulse assay, APL 6
(N329S), APL 7 (N329T), APL 12 (G332A), and APL 13
(G332V) significantly reduced IL-17 production by CD4+ T
cells primed with rhGPI in the presence of hGPI325-339 (P <
0.01) (Figure 1b). We therefore considered these four APLs
as antagonistic APLs.
Inhibition of arthritis by antagonistic altered 
peptideligands
Since GPI peptide-induced arthritis is mediated by Th17 and
antagonistic APLs can suppress IL-17 production, we
explored the efficacy of the prepared APLs on the inhibition of
Table 1
hGPI325--339-derived altered peptide ligands used in the present study
325 to 339 I W Y I NCF GCETH AML
APL 1 -- -- N -- -- -- -- -- -- -- -- -- -- --
APL 2 -- -- Q -- -- -- -- -- -- -- -- -- -- --
APL 3 -- -- S -- -- -- -- -- -- -- -- -- -- --
APL 4 -- -- T -- -- -- -- -- -- -- -- -- -- --
APL 5 -- -- -- Q -- -- -- -- -- -- -- --
APL 6 -- -- -- S -- -- -- -- -- -- -- --
APL 7 -- -- -- T -- -- -- -- -- -- -- --
APL 8 -- -- -- -- N -- -- -- -- -- -- --
APL 9 -- -- -- -- Q -- -- -- -- -- -- --
APL 10 -- -- -- -- S -- -- -- -- -- -- --
APL 11 -- -- -- -- T -- -- -- -- -- -- --
APL 12 -- -- -- -- -- A -- -- -- -- -- --
APL 13 -- -- -- -- -- V -- -- -- -- -- --
APL 14 -- -- -- -- -- -- N -- -- -- -- --
APL 15 -- -- -- -- -- -- Q -- -- -- -- --
APL 16 -- -- -- -- -- -- S -- -- -- -- --
APL 17 -- -- -- -- -- -- T -- -- -- -- --
APL 18 -- -- -- -- -- -- -- N -- -- -- --
APL 19 -- -- -- -- -- -- -- Q -- -- -- --
APL 20 -- -- -- -- -- -- -- S -- -- -- --
The MHC binding sites exist at glucose-6-phosphate isomerase (GPI) 328 (I), GPI 331 (F) and GPI 334 (E) as indicated (underlined). The amino 
acid residues of the T-cell receptor contact sites at P0 (Y327), P2 (N329), P3 (C330), P5 (G332), P6 (C333), and P8 (T335) were substituted 
for the indicated peptides to design 20 types of altered peptide ligands (APLs).Available online http://arthritis-research.com/content/11/6/R167
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arthritis. First, we immunized DBA/1 mice with each APL
alone, and confirmed that no overt arthritis developed (data
not shown). DBA/1 mice were then co-immunized with
hGPI325-339 and each APL to explore the development of arthri-
tis. Mice co-immunized with APL 6, APL 12 and APL 13 devel-
oped significantly attenuated arthritis after day 12, and those
co-immunized with APL 7 after day 16, compared with mice
immunized with hGPI325-339 alone (P < 0.05) (Figure 2, upper
panel). Co-immunization with APL 13 also significantly sup-
pressed the incidence of arthritis (P < 0.05) (Table 2). Co-
immunization with hGPI325-339 and APL 15, an agonistic APL,
however, did not affect the severity or course of arthritis (Fig-
ure 2, middle panel). Moreover, mice co-immunized with
hGPI325-339 and OVA323-339 also had a similar course of arthri-
tis to hGPI325-339 alone (Figure 2, lower panel).
Identification of TCRVβ usage of hGPI325-339-specificTh17 
cells
To investigate the inhibitory mechanisms of the antagonistic
APLs, we explored TCRVβ usage of hGPI325-339-specific
CD4+ T cells. The CD4+ T cells primed with hGPI325-339 were
stimulated with hGPI325-339 in vitro and the TCRVβ repertoire
was analyzed by flow cytometry and compared with that
before stimulation. Stimulation with hGPI325-339 expanded the
population of CD4+ T cells with TCRVβ8.1 8.2 (Figure 3a).
We also found that much of IL-17 was produced by CD4+ T
cells with TCRVβ8.1 8.2 following stimulation with hGPI325-339
(Figure 3b). These data indicate that many hGPI325-339-spe-
cific Th17 cells use TCRVβ8.1 8.2.
Effect of antagonistic altered peptide ligands on 
differentiation of Th17 and regulatory T cells
In vitro analysis showed that the antagonistic APLs sup-
pressed IL-17 production, and that co-immunization with the
APLs inhibited the development of arthritis. We therefore
explored the effect of APLs on Th17 differentiation. Our previ-
ous report suggested that cross-reactivity of CD4+ T cells
primed with hGPI325-339 to mGPI325-339 was critical for the
development of arthritis. We therefore assessed the popula-
tion of mGPI325-339 reactive Th17 cells in the DLNs of mice co-
Figure 1
Altered peptide ligands markedly suppress IL-17 production by glucose-6-phosphate isomerase-primed CD4+ T cells Altered peptide ligands markedly suppress IL-17 production by glucose-6-phosphate isomerase-primed CD4+ T cells. Altered peptide ligand (APL) 
6, APL 7, APL 9, APL 12 and APL 13 markedly suppress IL-17 production by glucose-6-phosphate isomerase (GPI)-primed CD4+ T cells. Mice 
were sacrificed on day 8 after immunization. CD4+ T cells were purified from draining lymph node cells of recombinant human GPI (hGPI)-immunized 
DBA/1 mice, and CD11c+ antigen-presenting cells (APCs) were purified from spleen cells. (a) CD4+ T cells primed with hGPI and APCs were co-
cultured with 10 μM synthetic peptide for 72 hours. The supernatants were assayed for IL-17 by ELISA. P, positive control (hGPI325--339). (b) 
CD11c+ APCs were cultured with a suboptimal concentration GPI325--339 (3 μM) for 2 hours, washed twice to remove unbound peptides, and 30 
μM each antagonistic APL was added. After 18 hours of culture, CD4+ T cells (2 × 104/well) were added, and after an additional 72 hours of culture, 
the supernatants were assayed for IL-17 by ELISA. The inhibition ratio was calculated as stated in Pre-pulse assay. Data presented as average ± 
standard deviation of three culture wells. *P < 0.05, **P < 0.01 (Mann--Whitney U test). Representative data of two independent experiments.Arthritis Research & Therapy    Vol 11 No 6    Iwanami et al.
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immunized with each APL. IL-17 production by CD4+ T cells
with TCRVβ8.1 8.2 or other TCRVβ with stimulation of
mGPI325-339was not affected by co-immunization with APLs
(Figure 4a), and neither was affected IL-17 production with
hGPI325-339 (data not shown). Unexpectedly, IL-17 production
was considerable with stimulation of the corresponding APLs
(Figure 4b). ELISA showed undetectable levels of IL-4, and
the IL-10 production, and IFNγ production was not affected
(data not shown). Co-immunization with APLs did neither
affect the population of regulatory T cells nor the expression of
CD25 (Figure 5), and stimulation of DLN cells of co-immu-
nized mice with APLs in vitro did not induce the expansion of
regulatory T cells (data not shown).
Identification of TCRVβ usage of altered peptide ligand-
specific CD4+ T cells
The unexpected data mentioned above suggested that APL-
specific CD4+ T cells were developed by co-immunization. We
Figure 2
Co-immunization with antagonistic altered peptide ligands suppresses the development of arthritis Co-immunization with antagonistic altered peptide ligands suppresses the development of arthritis. Mice were co-immunized with antagonistic 
altered peptide ligand (APL) 6, APL 7, APL 12, APL 13 (upper panel), the agonistic APL 15 (middle panel) or OVA peptide (lower panel). Progres-
sion of arthritis was significantly suppressed in mice co-immunized with APL 6, APL 12 and APL 13 after day 12, and in mice co-immunized with 
APL 7 after day 16 (P < 0.05, Mann--Whitney U test). Data presented as mean arthritis score (± standard error of the mean) of four mice in one rep-
resentative experiment of at least two independent experiments.Available online http://arthritis-research.com/content/11/6/R167
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therefore investigated TCRVβ usage of APL-specific CD4+ T
cells. The CD4+ T cells primed with each APL were stimulated
with the corresponding APL in vitro and the TCRVβ repertoire
was analyzed by flow cytometry and compared with that
before stimulation. Stimulation with APL 6, APL 7 and APL 12
induced expansion of the population of CD4+ T cells with
TCRVβ8.1 8.2; however, this expansion was not so remarka-
ble as that of hGPI325-339-specific CD4+ T cells (Figures 3a
and 6). Interestingly, stimulation with APL 13 hardly induced
the expansion of the population of CD4+  T cells with
TCRVβ8.1 8.2 (Figure 6) or any other specific Vβ chain,
although each APL stimulation could proliferate CD4+ T cells
primed with the corresponding APL as efficiently as hGPI325-
339 (data not shown).
Effects of antagonistic altered peptide ligands on anti-
mouse glucose-6-phosphate isomerase antibody 
production
Since administration of anti-CD4 monoclonal Abs with immu-
nization prevents the development of arthritis and completely
inhibits the production of anti-mGPI Abs in GPI-induced arthri-
tis, mGPI is considered a thymus-dependent antigen to the
humoral immune response [26]. We therefore next investi-
gated the effects of APLs on antibody production. Co-immuni-
zation with APL 6, APL 7, APL 12 and APL 13 significantly
suppressed the titers of anti-mGPI Abs (P < 0.01, P < 0.005,
P < 0.001 and P < 0.001, respectively) (Figure 7). We also
investigated the anti-mGPI IgG isotype. Co-immunization with
APL 7, APL 12 and APL 13 significantly suppressed the titer
of anti-mGPI IgG1 isotype (P < 0.005, P < 0.001 and P <
0.01, respectively). Any other anti-mGPI IgG isotype was
hardly detected, however, and any bias to specific isotype was
not found as an effect of APL.
Discussion
APLs are considered useful for antigen-specific therapy of
autoimmune diseases and allergy. Treatments with APLs have
so far been tested in several autoimmune models, and espe-
cially experimental autoimmune encephalitis has been enthusi-
astically examined for APLs designed as a single amino acid
substitution of a TCR contact site. In experimental autoimmune
encephalitis in Lewis rats, co-immunization with the APL
(K91A) of myelin basic protein MBP87-99 strongly inhibited the
development of the disease by suppression of IFNγ and TNFα,
not T-cell proliferation [31]. Furthermore, another study of
experimental autoimmune encephalitis in SJL mice showed
that co-immunization with the APL (W144Q) of myelin prote-
olipid protein PLP139-151 also inhibited the disease, and that
the T-cell clone specific for the APL (W144Q) possessed the
Th0 or Th2 phenotype [32].
Although one study used conventional APLs in collagen-
induced arthritis [33], unconventional APLs with substitutions
at MHC binding sites were mainly tested in arthritis models.
Myers and colleagues reported that the analog peptide
(I260A, A261B(hydroxyproline), F263N) significantly sup-
pressed collagen-induced arthritis by inducing Th2 cells in
DBA/1 mice [34]. They also reported the suppression of col-
lagen-induced arthritis in HLA-DR1 and HLA-DR4 transgenic
mice using other analog peptides with substitutions at MHC
binding sites [35,36]. Another group reported also that the
antigen-specific proinflammatory response to the human carti-
lage glycoprotein-39 (263 to 275) epitope was suppressed in
DR4 transgenic mice by APLs with substitution at MHC bind-
ing sites [37].
In our study, we designed various APLs (N329S, N329T,
G332A, or G332V) of hGPI325-339 with substitutions at TCR
contact sites, and showed that co-immunization with the indi-
vidual APL significantly inhibited the development of arthritis.
Although the APLs had antagonism to Th17 primed with hGPI
cells in vitro (Figure 1), analysis of the mechanisms of the
effect of co-immunizing APLs showed normal development of
hGPI-325-339-specific Th17 cells and APL-specific Th17 cells
in vivo (Figure 4). Co-immunization with hGPI325-339 and the
APL might have induced both hGPI-325-339-specific Th17
clones and APL-specific Th17 clones by the adjuvant effects
of complete Freund's adjuvant and pertussis toxin.
Since both the TCR signal and the co-stimulatory signal are
essential for priming of naïve T cells, our data suggested the
potency of the APLs as agonists to some TCRs. It is likely that
Table 2
Effects of co-immunization with altered peptide ligands on the development of arthritis
Co-immunization Incidence Day of onset Maximum severity
None 8/8 10 ± 0.0 10.9 ± 1.4
APL 6 8/8 10 ± 0.0 7.5 ± 2.0*
APL 7 6/8 10 ± 0.0 7.8 ± 1.7*
APL 12 7/8 10.3 ± 0.8 5.0 ± 1.2**
APL 13 3/8† 10 ± 0.0 4.0 ± 0.0**
Mice were co-immunized with 10 μg glucose-6-phosphate isomerase hGPI325--339and 50 μg indicated antigen. Data presented as incidence or 
mean ± standard deviation. †P < 0.05 (Fisher's exact test). *P < 0.005, **P < 0.001 (Mann--Whitney U test).Arthritis Research & Therapy    Vol 11 No 6    Iwanami et al.
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an antigen acts as an agonist to one T-cell clone and as an
antagonist to another T-cell clone because any TCR can
cross-react with various antigens. Although the antigen specif-
icity is mainly determined by the complementary determining
regions, the different ratio of TCRVβ usage between hGPI325-
339-specific CD4+  T cells and APL-specific CD4+  T cells
(especially APL 13) indicates that each CD4+ T cell is a differ-
ent clone that leads to different antigen specificity, and does
not cross-react to the APLs and hGPI325-339 to conduct posi-
tive TCR signals, respectively. Our previous paper showed
that T cells primed with hGPI325-339  could cross-react to
mGPI325-339 and that the cross-reactivity to mGPI325-339 was
crucial for induction arthritis [27]. The findings that immuniza-
tion with the APLs (APL 6, APL 7, APL 12, APL 13) alone
Figure 3
Human glucose-6-phosphate isomerase-specific Th17 cells use TCRVβ8.1 8.2 Human glucose-6-phosphate isomerase-specific Th17 cells use TCRVβ8.1 8.2. Many glucose-6-phosphate isomerase hGPI325--339-specific Th17 
cells use TCRVβ8.1 8.2. Mice were immunized with 10 μg hGPI325--339, and draining lymph node cells on day 6 were stimulated with 20 μM 
hGPI325--339 in vitro. (a) Ratios of TCRVβ repertoire to CD4+ T cells. The TCRVβ repertoire of CD4+ T cells was analyzed by flow cytometry: before 
stimulation with hGPI325--339 in vitro for 72 hours, and after stimulation. (b) GoldiStop was added in the last 4 hours of the 24-hour culture. Flow 
cytometry analysis for IL-17 was gated in CD4high cells. Representative data of two independent experiments.Available online http://arthritis-research.com/content/11/6/R167
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Figure 4
Co-immunization with altered peptide ligands does not affect IL-17 production Co-immunization with altered peptide ligands does not affect IL-17 production. Mice were immunized with 10 μg glucose-6-phosphate isomerase 
hGPI325--339 and 50 μg each altered peptide ligand (APL). Draining lymph node cells on day 6 were stimulated for 24 hours in vitro (a) with 10 μM 
mouse GPI325--339 or (b) with 10 μM corresponding APL. GoldiStop was added in the last 4 hours of each culture. Flow cytometry analysis for IL-17 
and TCRVβ repertoire was gated in CD4high cells. None, immunization with no APL (hGPI325--339alone). Representative flow cytometry data of two 
independent experiments.Arthritis Research & Therapy    Vol 11 No 6    Iwanami et al.
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could not induce any overt arthritis indicated that APL-specific
T cells could not cross-react mGPI325-339 suggesting they do
not have potential for induction of arthritis.
One of the inhibitory mechanisms of APL is anergy. Allen and
colleagues reported that APL could induce anergy of T-cell
clones by partial activation [38], which was characterized by
an increase in cell volume and upregulation of CD25, without
cytokine production or cell proliferation. Another mechanism is
induction of anti-inflammatory T-cell lineages such as Th2/Th0
as well as regulatory T cells. Nicholson and colleagues
reported that co-immunization with PLP139-151  and APL
(W144L/H147R) did not inhibit the induction of PLP139-151-
specific T cells, but induced APL-specific Th2/Th0 phenotype
cells to suppress the progression of experimental autoimmune
encephalitis by stander suppression [39].
Figure 5
Co-immunization with altered peptide ligands neither induces regulatory T cells nor modulates CD25 expression Co-immunization with altered peptide ligands neither induces regulatory T cells nor modulates CD25 expression. Mice were immunized with 10 μg 
glucose-6-phosphate isomerase hGPI325--339 and 50 μg each altered peptide ligand (APL), and draining lymph node cells on day 6 were stained 
with Foxp3 and CD25. Flow cytometry analysis was gated in CD4+ cells. None, immunization with no APL (hGPI325--339 alone). Representative flow 
cytometry data of two independent experiments.Available online http://arthritis-research.com/content/11/6/R167
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In our system, however, neither of these mechanisms was
likely because the APLs did not inhibit IL-17 production and
cell proliferation with stimulation of mGPI325-339, and induction
of any anti-inflammatory and regulatory T cells was not
detected. Nevertheless, it is probable that APLs inhibit
mGPI325-339-specific T cells because our analysis showed sig-
nificant reductions of anti-mGPI Abs, which were Abs to thy-
mus-dependent antigen [26]. We assumed that competitive
bindings of APL to TCR in vivo were likely in our system; how-
ever, it cannot be denied that amino acid substitutions in pep-
tides, even those that are not directly involved in MHC binding,
might affect the overall structure of the peptide and biding
affinity to MHC. Taken together, competitive binding of the
APLs to hGPI325-339-specific TCR or MHC in vivo is consid-
ered most likely as an inhibitory mechanism of APLs in our sys-
tem.
The major interest in APLs is their clinical application; several
studies showed that APLs suppress autoreactive cells in RA
and Sjogren's syndrome [40,41]. Although clinical trials of
APL in RA have not yet been conducted, phase II clinical trials
in multiple sclerosis have been reported [42,43]. In one study
Figure 6
TCRVβ usage of altered peptide ligand-specific CD4+ T cells TCRVβ usage of altered peptide ligand-specific CD4+ T cells. TCRVβ usage of altered peptide ligand (APL)-specific CD4+ T cells was not remarka-
bly shifted to TCRVβ8.1 8.2. Mice were immunized with 10 μg each APL, and draining lymph node cells on days 7 to 9 were stimulated with 20 μM 
corresponding APL in vitro. Ratios of TCRVβ repertoire to CD4+ T cells. The TCRVβ repertoire of CD4+ T cells was analyzed by flow cytometry: 
before stimulation with the corresponding in vitro for 72 hours, and after stimulation.Arthritis Research & Therapy    Vol 11 No 6    Iwanami et al.
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of eight patients with multiple sclerosis, subcutaneous admin-
istration at 50 mg dose once-weekly of CGP77116 - an APL
with substitutions at multiple TCR contact sites of MBP83-99 -
resulted in the development of exacerbations in two patients
with enhancement of MBP83-99-reactive Th1 response [42].
Another double-blind placebo-controlled clinical trial included
142 patients who received various doses of subcutaneously
injected NBI5788, an APL of MBP83-99 with substitutions at
TCR contact sites [43]. In contrast to the former study, the
administration of 5 mg APL weekly significantly decreased
inflammatory lesions in the central nervous system. Unfortu-
nately, the study was halted because 9% of the patients devel-
oped hypersensitivity reactions, but none discontinued at a
dose of 5 mg in the double-blind phase whereas all patients
discontinued in the double-blind phase after receiving higher
doses of 20 or 50 mg. Low-dose APLs might therefore be use-
ful agents for antigen-specific therapies of autoimmune dis-
eases including RA, and their efficacy in RA might be more
promising than in multiple sclerosis because drugs can be
injected directly into the inflammatory lesions.
Figure 7
Co-immunization with altered peptide ligands suppresses production of antibodies to mouse glucose-6-phosphate isomerase Co-immunization with altered peptide ligands suppresses production of antibodies to mouse glucose-6-phosphate isomerase. Sera were taken on 
day 28 from mice co-immunized with 10 μg glucose-6-phosphate isomerase hGPI325--339 and 50 μg each altered peptide ligand (APL), and the titers 
of anti-mouse GPI IgG and IgG isotype were analyzed by ELISA. Each symbol represents a single mouse. Data presented as mean optimal density 
± standard deviation. *P < 0.01, **P < 0.005, ***P < 0.001 (Mann--Whitney U test).Available online http://arthritis-research.com/content/11/6/R167
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Finally, can GPI be a target of antigen-specific therapies in
RA? It has been reported that patients with severe forms of RA
retained high titers of anti-GPI Abs [44-47] and GPI-reactive
CD4+  T cells were detected among anti-GPI-Ab-positive
patients with RA [48]. These findings highlight autoimmune
responses to GPI are occurring in some patients with RA, and
GPI can be a target of antigen-specific therapies to them -
although further studies are needed to clarify the exact patho-
logical role of GPI in RA.
Conclusions
The results of the present study showed that APLs with sub-
stitutions at TCR contact sites inhibit GPI peptide-induced
arthritis. Novel antigen-specific therapies based on APLs may
prove beneficial in arthritis induced by autoimmune responses
to autoantigens.
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